{
 "awd_id": "0711621",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "SBIR Phase I:  Bioluminescence Resonance Energy Transfer Assays for Clinical Chemistry",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "F.C. Thomas Allnutt",
 "awd_eff_date": "2007-07-01",
 "awd_exp_date": "2007-12-31",
 "tot_intn_awd_amt": 99993.0,
 "awd_amount": 99993.0,
 "awd_min_amd_letter_date": "2007-05-17",
 "awd_max_amd_letter_date": "2007-05-17",
 "awd_abstract_narration": "This Small Business Innovation Research (SBIR) Phase I research project aims to develop a point-of-care assay for creatine kinase, an important toxicity biomarker, to screen for adverse drug reactions (ADRs) using whole blood. The assay will utilize bioluminescent resonance energy transfer (BRET) probes incorporating quantum dots. \r\n\r\nThe proposed technology is likely to impact toxicity testing, allowing physicians to test for potential ADR at an early stage and take corrective measures.  With over 50% of Medicare patients taking multiple medications, the probability of ADRs is high and any inexpensive and reliable test for toxicity would be of benefit to these individuals and society as a whole.  \r\n",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Daniel",
   "pi_last_name": "Sobek",
   "pi_mid_init": "",
   "pi_sufx_name": "",
   "pi_full_name": "Daniel Sobek",
   "pi_email_addr": "daniel_sobek@zymera.com",
   "nsf_id": "000100203",
   "pi_start_date": "2007-05-17",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Zymera Corporation",
  "inst_street_address": "5941 Optical Court",
  "inst_street_address_2": "",
  "inst_city_name": "San Jose",
  "inst_state_code": "CA",
  "inst_state_name": "California",
  "inst_phone_num": "6505157897",
  "inst_zip_code": "951381400",
  "inst_country_name": "United States",
  "cong_dist_code": "19",
  "st_cong_dist_code": "CA19",
  "org_lgl_bus_name": null,
  "org_prnt_uei_num": null,
  "org_uei_num": null
 },
 "perf_inst": {
  "perf_inst_name": "Zymera Corporation",
  "perf_str_addr": "5941 Optical Court",
  "perf_city_name": "San Jose",
  "perf_st_code": "CA",
  "perf_st_name": "California",
  "perf_zip_code": "951381400",
  "perf_ctry_code": "US",
  "perf_cong_dist": "19",
  "perf_st_cong_dist": "CA19",
  "perf_ctry_name": "",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537100",
   "pgm_ele_name": "SBIR Phase I"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "5371",
   "pgm_ref_txt": "SMALL BUSINESS PHASE I"
  },
  {
   "pgm_ref_code": "9183",
   "pgm_ref_txt": "GENERAL FOUNDATIONS OF BIOTECHNOLOGY"
  },
  {
   "pgm_ref_code": "BIOT",
   "pgm_ref_txt": "BIOTECHNOLOGY"
  }
 ],
 "app_fund": [
  {
   "app_code": "0107",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "490100",
   "fund_code": "app-0107",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2007,
   "fund_oblg_amt": 99993.0
  }
 ],
 "por": null
}